| 玻璃体腔注射雷珠单抗治疗CSME及NCSME的临床观察 |
| |
| 引用本文： | 靳琳,潘庆敏,胡磊.玻璃体腔注射雷珠单抗治疗CSME及NCSME的临床观察[J].山东大学耳鼻喉眼学报,2017(2):96-98. |
| |
| 作者姓名： | 靳琳 潘庆敏 胡磊 |
| |
| 作者单位： | 泰山医学院,山东泰安,271000 |
| |
| 摘 要： | 目的研究玻璃体腔注射雷珠单抗(IVR)治疗有临床意义的黄斑水肿(CSME)及非临床意义的黄斑水肿(NCSME)患者的临床效果。方法将糖尿病黄斑水肿(DME)的患者77例,分为CSME组及NCSME组,行IVR治疗,比较治疗前后患者的最佳矫正视力(BCVA)和黄斑水肿最高高度。结果两组治疗1个月后,BCVA较治疗前差异均有统计学意义(P0.05)。两组间比较,治疗前后各时间点黄斑水肿最高高度差异均无统计学意义(P0.05)。结论 CSME及NCSME患者行IVR治疗后黄斑水肿高度降低,但黄斑水肿高度不能完全反映患者视力情况。
|
| 关 键 词： | 糖尿病性黄斑水肿 最高高度 最佳矫正视力 雷珠单抗 |
Clinical observation on the treatment of CSME and NCSME by intravitreal injection of ranibizumab |
| |
| JIN Lin,PAN Qingmin,HU Lei.Clinical observation on the treatment of CSME and NCSME by intravitreal injection of ranibizumab[J].Journal of Otolaryngology and Ophthalmology of Shandong University,2017(2):96-98. |
| |
| Authors: | JIN Lin PAN Qingmin HU Lei |
| |
| Abstract: | Objective To explore the clinical efficacy of clinically significant macular edema (CSME) and non-clinically significant macular edema (NCSME) treated with Ranibizumab intravitreal injection.Methods A total of 77 BRVO-ME cases were divided into 2 groups:CSME group (n =51) and NCSME group (n =26).The two groups received Ranibizumab intravitreal injection.Best corrected visual acuity (BCVA) and highest thickness of macular edema of the two groups were observed.Results One months after treatment,BCVA of the two groups were improved (P ＜ 0.05).No significant difference between two groups was found in the highest thickness of macular edema (P ＞ 0.05).Conclusion Ranibizumab intravitreal injection can improve visual acuity and reduce the highest thickness of macular edema in patients with CSME and NCSME.The highest thickness of macular edema can not completely reflect the visual acuity. |
| |
| Keywords: | Diabetic macular edema Highest thickness Best corrected visual acuity Ranibizumab |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
